Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...
today announced that initial data from the Phase 1/2 OTC-HOPE clinical trial evaluating in vivo gene editing candidate ECUR-506 in neonatal onset ornithine transcarbamylase (OTC) deficiency will ...
Research reveals how sleep quality, exercise intensity, nutrition timing, and stress management can naturally optimize growth hormone production.
The global industry was valued at US$ 527.5 Mn in 2024 and is projected to exceed US$ 771.0 Mn by 2035, growing at a CAGR of ...
12d
Arcturus Therapeutics Holdings Inc. a publié ses résultats pour l'exercice clos le 31 décembre 2024. Pour l'ensemble de ...
Arcturus Therapeutics Holdings Inc. a publié ses résultats pour le quatrième trimestre clos le 31 décembre 2024. Pour le ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
A new study published in the journal of BMC Oral Health highlighted the role of salivary microbiota and polyamines in ...
In a recent study published in Science Advances, researchers led by Prof. Li Xinjian from the Institute of Biophysics of the ...
DURHAM, N.C. - Precision BioSciences, Inc. (NASDAQ: DTIL ), une société d’édition génique actuellement cotée à 5,04 $ et affichant un gain de 32 % depuis le début de l’année, a reçu l’autorisation de ...
Reports Q4 revenue $22.8M, consensus $44.64M. “We continue to progress our flagship rare disease programs and look forward to sharing ...
Ce lundi, l’analyste Whitney Ijem de Canaccord Genuity a ajusté l’objectif de cours d’Arcturus Therapeutics (NASDAQ: ARCT) à 68$ contre 74$ précédemment, tout en maintenant sa recommandation d’Achat s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback